摘要
目的探讨奥曲肽联合生长激素治疗ICU重症急性胰腺炎患者的临床疗效,为临床治疗决策提供依据。方法回顾性分析在我院ICU住院,使用醋酸奥曲肽注射液(单用组,35例)与醋酸奥曲肽注射液+重组人生长激素注射液(联用组,33例)治疗重症急性胰腺炎患者的临床资料。对两组患者治疗前后的APACHEⅡ评分,血浆白蛋白,平均住院天数,严重并发症的发生率及病死率进行统计分析。结果治疗后,联用组患者APACHEⅡ评分(6.3±2.5)、血浆白蛋白(3.6±0.7)、平均住院天数(32.3±4.1)及严重并发症发生率(30.3%)与单用组比较,差异具有统计学意义(P<0.05);联用组患者的病死率(6.1%)与单用组比较,差异无统计学意义(P>0.05)。结论奥曲肽联合生长激素治疗ICU重症急性胰腺炎具有较好的临床疗效。
Objective To discuss the clinic efficacy of octreotide joint growth hormone in treatment of severe acute pancreatitis in ICU and provide basis for clinical medical decision-making.Methods The clinical data of severe acute pancreatitis treated by octreotide acetate injection（medication alone group,35 cases） and octreotide Acetate injection ＋ recombinant human growth hormone injection（combination group,33 cases） in ICU that was retrospectively analyzed.The APACHE Ⅱ,ALB,average hospitalization days,incidence of serious complications and mortality were statistically analyzed.Results There were significant differences of APACHE Ⅱ（6.3±2.5）,ALB（3.6±0.7）,average hospitalization days（32.3±4.1）and incidence（30.3%）of serious complications in combination group compared to medication alone group（P 0.05）;there were no significant differences of mortality（6.1%）in combination group compared to medication alone group（P0.05）.Conclusion Octreotide joint growth hormone in treatment of severe acute pancreatitis in ICU that had better clinic efficacy.
出处
《中国医药指南》
2013年第6期41-42,共2页
Guide of China Medicine
关键词
重症急性胰腺炎
奥曲肽
生长激素
ICU
临床疗效
Severe acute pancreatitis
Octreotide
Growth hormone
Intensive Care Unit（ICU）
Clinic efficacy
